- Home
- APRE vs CWD Comparison
APRE vs CWD Comparison
Compare APRE & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- CWD
- Stock Information
- Founded
- APRE 2006
- CWD 2009
- Country
- APRE United States
- CWD United States
- Employees
- APRE N/A
- CWD N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- CWD Real Estate
- Sector
- APRE Health Care
- CWD Finance
- Exchange
- APRE Nasdaq
- CWD Nasdaq
- Market Cap
- APRE 13.5M
- CWD 12.1M
- IPO Year
- APRE 2019
- CWD 2023
- Fundamental
- Price
- APRE $1.50
- CWD $0.24
- Analyst Decision
- APRE Strong Buy
- CWD
- Analyst Count
- APRE 2
- CWD 0
- Target Price
- APRE $15.50
- CWD N/A
- AVG Volume (30 Days)
- APRE 29.2K
- CWD 786.9K
- Earning Date
- APRE 05-13-2025
- CWD 05-08-2025
- Dividend Yield
- APRE N/A
- CWD N/A
- EPS Growth
- APRE N/A
- CWD N/A
- EPS
- APRE N/A
- CWD N/A
- Revenue
- APRE $1,502,581.00
- CWD $51,119,000.00
- Revenue This Year
- APRE N/A
- CWD N/A
- Revenue Next Year
- APRE N/A
- CWD $35.72
- P/E Ratio
- APRE N/A
- CWD N/A
- Revenue Growth
- APRE 157.63
- CWD N/A
- 52 Week Low
- APRE $1.41
- CWD $0.25
- 52 Week High
- APRE $5.90
- CWD $1.04
- Technical
- Relative Strength Index (RSI)
- APRE 27.07
- CWD 22.38
- Support Level
- APRE $1.41
- CWD $0.20
- Resistance Level
- APRE $1.59
- CWD $0.57
- Average True Range (ATR)
- APRE 0.11
- CWD 0.07
- MACD
- APRE 0.02
- CWD -0.03
- Stochastic Oscillator
- APRE 18.60
- CWD 9.64
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.